5 Early-Stage Names With the Cash to Back Up the Story $ONDS $ABCL $SMR $JOBY $QS $ONDS — The defense and autonomous systems story here has been one of the fastest-scaling in the space, and the balance sheet backs it up. Ondas ended Q2 with roughly $1.4 billion in cash, cash equivalents, restricted cash, and short-term investments, alongside a $757 million backlog that grew 66% sequentially. Revenue is scaling fast too — Q2 came in at $83.8 million, up more than 13x year-over-year, with full-year guidance raised to $525–$550 million. The bear case worth knowing: a chunk of that cash pile has already been earmarked for recent acquisitions (DZYNE, CyberHawk), so the fortress balance sheet is partly a function of equity raises funding a roll-up strategy — worth watching how disciplined that stays. $ABCL — A biotech name with a genuinely clean balance sheet: over $565 million in cash and marketable securities, plus access to roughly $110 million in committed government funding, giving management a stated runway of at least three years. Two new partnerships with Jazz Pharmaceuticals and Vertex added over $110 million in non-dilutive upfront cash this year alone — a good sign that the platform is monetizing without constant capital raises. The lead program, ABCL635, already delivered its Phase 2 catalyst on August 10 — a single dose cut moderate-to-severe hot flash frequency by 83% versus 33% for placebo at week 4, hitting statistical significance with a clean tolerability profile. Next catalyst to watch is ABCL575 Phase 1 data, expected Q4 2026. $JOBY — This is the standout on pure balance sheet strength: roughly $2.3 billion in cash and short-term investments as of the end of Q2. That's real ammunition heading into what's shaping up to be the most important stretch yet — first eVTOL passenger flights targeted for later this year, alongside continued FAA certification progress. The offset: cash burn is heavy, with the company using about $202 million in the quarter, so the runway is strong but not infinite. $SMR — Liquidity here has ballooned to about $1.9 billion in cash, cash equivalents, and investments, up roughly $900 million in a single quarter. Revenue is essentially nonexistent right now (a byproduct of project timing, not demand), so this is a pure binary-catalyst setup — the whole thesis hinges on ENTRA1 closing a definitive agreement with the Tennessee Valley Authority. If that lands, the cash position gives NuScale the ability to execute immediately without needing to raise into a potential re-rate. $QS — Total liquidity of $859 million, split between cash/equivalents and marketable securities, funds continued scaling of the Eagle Line production process and expansion into new verticals including AI data center batteries (QSDC) and defense/aerospace (QSAS). Management has guided full-year Adjusted EBITDA loss of $250–$275 million, so the cash pile is a multi-year runway rather than a war chest for aggressive expansion — still, it removes near-term financing risk while the company works toward commercialisation. each of these names can fund its own roadmap for years without going back to the well, which takes one major risk off the table for early-stage exposure. That doesn't remove execution risk — cash doesn't guarantee contracts, certifications, or clinical data — but it does buy time for the thesis to play out without shareholders getting diluted along the way. Not financial advice.